Ï㽶ÊÓƵ

In separate clinical trials, a drug called ocrelizumab has been shown to reduce new attacks in patients with relapsing remitting multiple sclerosis (MS), and new symptom progression in primary progressive MS.

Three studies conducted by an international team of researchers, which included Amit Bar-Or and Douglas Arnold from the Montreal Neurological Institute and Hospital of Ï㽶ÊÓƵ, have discovered that ocrelizumab can significantly reduce new attacks in patients with relapsing MS, as well as slow the progression of symptoms caused by primary progressive MS.

Classified as: Research, The Neuro, Amit Bar-Or, MS, health and lifestyle, Douglas Arnold, ocrelizumab
Category:
Published on: 9 Jan 2017

Drug shown to reduce new attacks/symptom progression in some patients

In separate clinical trials, a drug called ocrelizumab has been shown to reduce new attacks in patients with relapsing remitting multiple sclerosis (MS), and new symptom progression in primary progressive MS.

Classified as: MS, ocrelizumab, Amit Bar-Or, Douglas Arnold, Multiple Sclerosis
Published on: 22 Dec 2016

May 2016 - Multiple Sclerosis Awareness Month

Ìý

Multiple sclerosis treatment and research has long been a focus at the Montreal Neurological Institute and Hospital, known simply as The Neuro, an illustrious member of Ï㽶ÊÓƵ and the Ï㽶ÊÓƵ Health Centre. Indeed, The Neuro introduced Canada’s first MS clinic. The clinic’s highly specialized staff employs the latest research data and treatment methods in a clinical atmosphere of innovation and progress.

Classified as: Multiple Sclerosis, Research, MS, neuroscience, Yves Lapierre, Paul Giacomini, Amit Bar-Or, Jack Antel, Alyson Fournier, Douglas Arnold, Tim Kennedy, daria trojan
Category:
Published on: 2 May 2016

A new study led by researchers at the Montreal Neurological Institute and Hospital of Ï㽶ÊÓƵ and the MUHC, gets closer to identifying the mechanisms responsible for multiple sclerosis and makes headway in the search for better treatments.

Classified as: Montreal Neurological Institute, Multiple Sclerosis, Amit Bar-Or, MS, B cell depletion therapy, B cell depletion, B cell
Category:
Published on: 23 Oct 2015

A new study led by researchers at the Montreal Neurological Institute and Hospital of Ï㽶ÊÓƵ and the MUHC, gets closer to identifying the mechanisms responsible for multiple sclerosis and makes headway in the search for better treatments.

Classified as: Amit Bar-Or
Category:
Published on: 22 Oct 2015

The Montreal Neurological Institute and Hospital – The Neuro at Ï㽶ÊÓƵ and the MUHC has Canada’s oldest MS clinic but is always innovating - striving for progress and better treatments for patients.

What’s new in MS at The Neuro

Classified as: Multiple Sclerosis, neuroscience, Montreal Neurological Institute and Hospital, The Neuro, mcgill faculty of medicine research, Neuro Giving, Alyson Fournier, Douglas Arnold, Tim Kennedy, daria trojan, Yves Lapierre, Paul Giacomini, Amit Bar-Or, Jack Antel
Category:
Published on: 7 May 2015

Powerful treatment improves patients’ lives and provides new insight into mechanisms of the disease

Classified as: neuroscience, brain, treatment, neurological, Multiple Sclerosis, Amit Bar-Or, bone marrow, MS, stem cells, transplant
Category:
Published on: 26 Mar 2013
Back to top